BIRMINGHAM, Ala. (Dow Jones)--Biocryst Pharmaceuticals Inc.'s (BCRX) fourth-quarter losses widened, as a result of higher research and development costs.
In a press release Wednesday, the biopharmaceutical concern said losses grew to $7.16 million, or 27 cents a share, from $5.29 million, or 24 cents a share, a year earlier.
Total expenses rose to $7.51 million from $5.6 million, as research and development costs increased 28.5% to $6.04 million.
Revenue declined to $21,000 from $178,000 because Biocryst completed work related to a National Institutes of Health grant for a hepatitis C program.
Additionally, Biocryst expects Roche Holding AG (RHHBY) to start Phase II trials of BCX-4208 as a psoriasis treatment during 2006. Roche licensed the compound from Biocryst in November. BCX-4208 is a treatment candidate against chronic conditions including autoimmune diseases and transplant rejection.
according to the Merril Lynch conference schedule, NTMD doesnt present until 4:00 pm today. So either they are going to say something bad and that has leaked or the down move so far today isnt associated with that presentation.
Market Data 
Markets 
AI
